Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 5/20 | 0.62 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005892 | 0.90 | VEGFA (0.58) | VEGFAEGLN1FAAHMEN1KMT2A | |
| SCHEMBL17005887 | 0.90 | VEGFA (0.66) | VEGFAEGLN1FAAHPOLBPKM | |
| SCHEMBL17005929 | 0.89 | VEGFA (0.63) | VEGFAEGLN1POLBPKMMEN1 | |
| SCHEMBL17005959 | 0.88 | VEGFA (0.66) | VEGFAEGLN1FAAHPOLBMEN1 | |
| SCHEMBL17005917 | 0.88 | VEGFA (0.60) | VEGFAEGLN1FAAHMEN1KMT2A | |
| SCHEMBL28566307 | 0.87 | VEGFA (0.82) | VEGFAEGLN1FAAHPOLBPKM | |
| SCHEMBL14889521 | 0.86 | VEGFA (0.72) | VEGFAEGLN1FAAHPOLBMEN1 | |
| SCHEMBL17005956 | 0.86 | VEGFA (0.56) | VEGFAEGLN1FAAHPKMMEN1 | |
| SCHEMBL20763926 | 0.86 | VEGFA (0.83) | VEGFAEGLN1FAAHMEN1KMT2A | |
| SCHEMBL17005933 | 0.85 | ALDH1A1 (0.57) | VEGFAEGLN1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107542-B1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | VEGFA 4681/4885EGLN1 102/4885FAAH 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.